Loading
ARX517 is an experimental antibody-drug conjugate for metastatic prostate cancer, aimed at the protein PSMA. Ambrx developed it and Johnson & Johnson took it over when it bought Ambrx in 2024.
ARX517 is an antibody-drug conjugate in which a humanised anti-PSMA IgG1 antibody is covalently conjugated to two molecules of a proprietary microtubule-disrupting toxin, AS269, according to its registry record. It came to Johnson & Johnson with the acquisition of Ambrx Biopharma, announced in January 2024. The phase 1 trial (NCT04662580), now sponsored by Janssen Research & Development as ARX517/JNJ-95298177, tests it alone or with apalutamide or abiraterone in metastatic prostate cancer and is active but no longer recruiting. A second phase 1 trial (NCT07082920) combines it with JNJ-78278343. No results are recorded here.
A humanised antibody against PSMA, a protein on prostate cancer cells, is joined at two sites to a microtubule-disrupting toxin called AS269, which stops the cancer cell dividing. Connects to PSMA.
1.ARX517's antibody arm binds PSMA on the surface of the cancer cell.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-01-08 | Ambrx to Johnson & Johnson ARX517 (PSMA ADC) and ARX788 (HER2 ADC) with site-specific conjugation technology | Acquisition | not disclosed | $2.0bn | source |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ARX517" OR ABSTRACT:"ARX517" OR TITLE:"JNJ-95298177" OR ABSTRACT:"JNJ-95298177") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARX517, not a curated reading list.
Shares Antibody-drug conjugate (ADC) and the tags pipeline, deal-asset.
Shares Antibody-drug conjugate (ADC) and the tags pipeline, deal-asset.
Shares Antibody-drug conjugate (ADC) and the tags pipeline, deal-asset.
Shares Antibody-drug conjugate (ADC) and the tags pipeline, deal-asset.
Shares PSMA, Antibody-drug conjugate (ADC), Prostate cancer and the tag pipeline.
Shares Antibody-drug conjugate (ADC) and the tags pipeline, deal-asset.
Shares Prostate cancer and the tags pipeline, deal-asset.
Shares the tags pipeline, deal-asset.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/